Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

If AI Is the Engine and Patient Data Is its Fuel, Then Who’s in the Driver’s Seat?

Posted by Paul Darling on Wed, Oct 31, 2018

Pratap Khedkar co-wrote this blog post, the third in a series on ZS’s 2018 AI in Healthcare study, with Paul Darling.

Each time you visit the doctor, it’s the same scenario: You rattle off a bunch of information like medical history, lifestyle behaviors and choices, and current complaints, while she pounds away at a keyboard. You might have access to a portion of your medical record through a web-based patient portal, but otherwise that content is under the provider’s lock and key (unless you’re a New Hampshire resident). Don’t you wonder what your full electronic health record holds? Stakeholders throughout the healthcare ecosystem do, too.

Read More

Topics: Pratap Khedkar, Paul Darling, artificial intelligence, healthcare model, patient data, AI in Healthcare study, interoperability, digital connected health

Has Gawande Found the Right Man for the Job?

Posted by Pratap Khedkar on Thu, Sep 20, 2018

Paul Darling co-authored this blog post with Pratap Khedkar.

What kind of skills will it take to run the day-to-day operations for a potentially paradigm-shifting undertaking in U.S. healthcare delivery? It turns out that it's hands-on experience helping patients navigate the complexities of healthcare options and helping employers control healthcare costs, powered by an undercurrent of digital health expertise.

Read More

Topics: Pratap Khedkar, digital health, data and analytics, BerkshAmazMorgan, healthcare costs, employer-driven healthcare, patient data

DNA-Based Data Is a Hot Commodity, and Pharma Is Buying

Posted by ZS Editors on Wed, Aug 01, 2018

As the pharmaceutical industry continues along the path to precision medicine, drug discovery efforts are just one aspect of the business that increasingly will be fueled by data. A flurry of deals, including GlaxoSmithKline’s $300-million, four-year investment in 23andMe, gives us a window into how pharma companies are forming partnerships and striking deals to tap into stores of data to identify new R&D targets and fill clinical trials.

Read More

Topics: pharma manufacturer, new partnerships, data acquisition strategy, patient data, genomic data, R&D targets

Subscribe to The Active Ingredient
SUBSCRIBE

Get 'THE ACTIVE INGREDIENT' Updates

Subscribe to receive email notifications whenever new blog posts are published.

×